Ribbskottet AB increases its stake in Xspray Pharma
STOCKHOLM - September 24, 2018. Xspray Pharma (Nasdaq First North: XSPRAY) (“Xspray”) has received information that Ribbskottet AB has purchased a total of 223,000 shares in the company from Recipharm Venture Fund AB. The transfer took place outside the stock exchange. Ribbskottet’s holding in Xspray now amounts to 10 percent of the number of shares and votes, which means that Ribbskottet becomes Xspray’s second-largest shareholder. The sale was made at the current stock price.Ribbskottet AB has since Xspray’s introduction on First North in September 2017 been one of its ten largest owners.
Two-thirds through 2018, the Lund based company Emerse has already exceeded last year's performance with a turnover of 35 million; a 92% growth compared with the same period in 2017.This outcome demonstrates that Emerse's proprietary technology platform has gained more customers who understand that programmatic ad purchases need not be problematic. Emerse's reputation for being an easy-to-use DSP (Demand Side Platform), combined with high levels of customer service and support, are believed to be behind this success.
- More and more advertisers see what kind of results can be achieved
